GlassScriptPhysician profile
Phyllis J Henderson
NPI 1487863999
$565.75
in general payments reported to CMS, 2019-2025
10 companies · $96.63 in 2025
The $96.63 reported for 2025 was less than what a typical Addiction Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $152).
See the full distribution for Addiction Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.29 · 2022: $66.43 · 2023: $304 · 2024: $83.22 · 2025: $96.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $484.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $144.12 | 2023 | Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.86 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $69.05 | 2023-2025 | Invega, Risperdal, Invega Trinza |
| Axsome Therapeutics, INC. | $67.03 | 2022-2025 | Auvelity |
| Alkermes, INC. | $45.01 | 2023-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $38.48 | 2023-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $32.12 | 2024 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $16.81 | 2025 | |
| Seqirus USA INC | $15.29 | 2021 | |
| Eisai INC. | $13.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.